Here are the 10-Q quarterly reports from Attovia Therapeutics, Inc. (ATTO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATTO filings page.
Attovia Therapeutics, Inc. (ATTO) reported unaudited results for the quarter and six months ended June 30, 2026, reflecting continued investment in its immune‑mediated disease pipeline and preparations for becoming a public company. For the first half of 2026, revenue was $0.45 million from a collaboration with EndPath, while operating expenses rose to $42.2 million, driven by $35.7 million of research and development spending and $6.5 million of general and administrative costs.
This produced a first‑half net loss of $39.3 million, compared with $29.6 million a year earlier, and an accumulated deficit of $150.4 million as of June 30, 2026. Cash, cash equivalents and marketable securities totaled $115.1 million at quarter‑end. Subsequent to the period, Attovia completed an IPO raising approximately $305.4 million in net proceeds and effected a 1‑for‑9.29 reverse stock split, with all share and per‑share data retrospectively adjusted. Management states that existing cash, cash equivalents and marketable securities together with IPO proceeds are expected to fund planned operations into 2030.